Ameliorating effects of N-acetyl cysteine against early liver damage of radioiodine in rats.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
pubmed:
22
6
2021
medline:
29
1
2022
entrez:
21
6
2021
Statut:
ppublish
Résumé
The present study was aimed to explore the potential ameliorating effects of N-acetyl cysteine (NAC) against radioiodine (RAI)-induced early liver damage. Thirty Wistar Albino male rats were arbitrarily allocated into three groups each containing 10 rats: the control group (group 1); the RAI group (group 2), oral 111 MBq/kg radioiodine was administered to rats; the RAI + NAC group (group 3), 150 mg/kg/day intraperitoneal NAC treatment was initiated 3 days prior to the RAI administration and continued for 10 days. Liver samples were obtained 24 h after the last dose of NAC therapy for biochemical and histopathologic evaluation. In the RAI + NAC group, the histopathologic damage was found significantly less than in the RAI group for whole parameters except inflammatory cell infiltration (P < 0.05). Unlike the RAI group which had marked histopathologic damage, the RAI + NAC group had only mild histologic activity index scores with no granuloma formation observed. Oxidative stress parameters were demonstrated that the NAC treatment significantly decreased the tissue malondialdehyde (MDA) and catalase levels and increased the total sulfhydryl (total sulfhydryl) levels when compared to the RAI group (P < 0.01). The outcomes of the study exhibited that the NAC treatment improved RAI-induced early liver damage. This improving effect considered to be caused by its antioxidant, anti-inflammatory, and likely vasodilator properties of NAC. Having advantages such as inexpensive, easy access, and tolerability, the NAC can be used as a radioprotective agent, especially in patients with liver diseases and requiring RAI treatment.
Identifiants
pubmed: 34149008
doi: 10.1097/MNM.0000000000001454
pii: 00006231-202111000-00002
doi:
Substances chimiques
Acetylcysteine
WYQ7N0BPYC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1195-1201Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lee SL. Radioactive iodine therapy. Curr Opin Endocrinol Diabetes Obes 2012; 19:420–428.
Wyszomirska A. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nucl Med Rev Cent East Eur 2012; 15:120–123.
Changlai SP, Chang PJ, Chen CY. Biodistribution and dosimetry of (131)I in thyroidectomy patients using semiquantitative gamma-camera imaging. Cancer Biother Radiopharm 2008; 23:759–766.
Tuttle RM, Becker DV, Hurley JR. Radioiodine treatment of thyroid diseases. Sandler MP, Coleman RE, Patton JA, Wackers FJ, Gottschalk A, editors. In: Diagnostic nuclear medicine. Philadelphia: Lippincott Williams & Wilkins; 2003. pp. 653–670.
Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, Eftekhari M. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun 2014; 35:808–817.
Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, et al. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer 2011; 56:191–201.
Omür O, Akgün A, Ozcan Z, Sen C, OzkiIiç H. Clinical implications of diffuse hepatic uptake observed in postablative and post-therapeutic I-131 scans. Clin Nucl Med 2009; 34:11–14.
Vasil’ev LIa, Rozdil’skii SI, Tkachenko GI. Radionuklidnye issledovaniia funktsii pecheni i pochek pri rake shchitovidnoi zhelezy posle radioiodoterapii [Radionuclide research on liver and kidney function in thyroid cancer after radioiodine therapy]. Med Radiol (Mosk) 1987; 32:38–41.
Kismet K, Sadic M, Bag YM, Atilgan HI, Koca G, Onalan AK, et al. Hepatoprotective effect of dexmedetomidine against radioiodine toxicity in rats: evaluation of oxidative status and histopathological changes. Int Surg 2016; 101:176–184.
Atilgan HI, Yumusak N, Sadic M, Gultekin SS, Koca G, Ozyurt S, et al. Radioprotective effect of montelukast sodium against hepatic radioiodine (131I) toxicity: a histopathological investigation in the rat model. Ankara Univ Vet Fak Derg 2015; 62:37–43.
Lin R, Banafea O, Ye J. I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer. BMC Gastroenterol 2015; 15:56.
Jhummon NP, Tohooloo B, Qu S. Iodine-131 induced hepatotoxicity in previously healthy patients with Grave’s disease. Thyroid Res 2013; 6:4.
Azzam EI, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. Cancer Lett 2012; 327:48–60.
Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 2007; 12:738–747.
Blumberg AL, Nelson DF, Gramkowski M, Glover D, Glick JH, Yuhas JM, Kligerman MM. Clinical trials of WR-2721 with radiation therapy. Int J Radiat Oncol Biol Phys 1982; 8:561–563.
Klein-Schwartz W, Doyon S. Intravenous acetylcysteine for the treatment of acetaminophen overdose. Expert Opin Pharmacother 2011; 12:119–130.
Moreno C, Langlet P, Hittelet A, Lasser L, Degré D, Evrard S, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol 2010; 53:1117–1122.
Samuhasaneeto S, Thong-Ngam D, Kulaputana O, Patumraj S, Klaikeaw N. Effects of N-acetylcysteine on oxidative stress in rats with non-alcoholic steatohepatitis. J Med Assoc Thai 2007; 90:788–797.
Khoshbaten M, Aliasgarzadeh A, Masnadi K, Tarzamani MK, Farhang S, Babaei H, et al. N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease. Hepat Mon 2010; 10:12–16.
Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991; 324:1852–1857.
Brown SL, Kolozsvary A, Liu J, Jenrow KA, Ryu S, Kim JH. Antioxidant diet supplementation starting 24 hours after exposure reduces radiation lethality. Radiat Res 2010; 173:462–468.
Neal R, Matthews RH, Lutz P, Ercal N. Antioxidant role of N-acetyl cysteine isomers following high dose irradiation. Free Radic Biol Med 2003; 34:689–695.
Kim HJ, Kang SU, Lee YS, Jang JY, Kang H, Kim CH. Protective effects of N-acetylcysteine against radiation-induced oral mucositis in vitro and in vivo. Cancer Res Treat 2020; 52:1019–1030.
Shukla PK, Gangwar R, Manda B, Meena AS, Yadav N, Szabo E, et al. Rapid disruption of intestinal epithelial tight junction and barrier dysfunction by ionizing radiation in mouse colon in vivo: protection by N-acetyl-l-cysteine. Am J Physiol Gastrointest Liver Physiol 2016; 310:G705–G715.
Kurashige T, Shimamura M, Nagayama Y. N-acetyl-L-cysteine protects thyroid cells against DNA damage induced by external and internal irradiation. Radiat Environ Biophys 2017; 56:405–412.
Farmer EE, Davoine C. Reactive electrophile species. Curr Opin Plant Biol 2007; 10:3806.
Prakash M, Shetty MS, Tilak P, Anwar N. Total thiols: biomedical importance, and their alteration in various disorders. Online J Health Allied Scs 2009; 8:2.
Chelikani P, Fita I, Loewen PC. Diversity of structures and properties among catalases. Cell Mol Life Sci 2004; 61:192–208.
Wasowicz W, Nève J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. Clin Chem 1993; 39:2522–2526.
Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968; 25:192–205.
Hadwan MH. Simple spectrophotometric assay for measuring catalase activity in biological tissues. BMC Biochem 2018; 19:7.
Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696–699.
Ishak KG. Pathologic features of chronic hepatitis. A review and update. Am J Clin Pathol 2000; 113:40–55.
Barlas AM, Sadic M, Atilgan HI, Bag YM, Onalan AK, Yumusak N, et al. Melatonin: a hepatoprotective agent against radioiodine toxicity in rats. Bratisl Lek Listy 2017; 118:95–100.
Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343:180–184.
Chughlay MF, Kramer N, Werfalli M, Spearman W, Engel ME, Cohen K. N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocol. Syst Rev 2015; 4:84.
Blokhina O, Virolainen E, Fagerstedt KV. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot 2003; 91 Spec No:179–194.
Pereira-Filho G, Ferreira C, Schwengber A, Marroni C, Zettler C, Marroni N. Role of N-acetylcysteine on fibrosis and oxidative stress in cirrhotic rats. Arq Gastroenterol 2008; 45:156–162.
Setshedi M, Longato L, Petersen DR, Ronis M, Chen WC, Wands JR, de la Monte SM. Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol Clin Exp Res 2011; 35:2139–2151.